Sun Pharmaceutical Industries’ subsidiary Sun Laboratories is planning to hit the domestic bond market in order to raise up to Rs 1,000 crore to fund an internal restructuring. The Mumbai-based drug maker has divided the issue into two parts of Rs 500 crore, one maturing in two years and the other in three years. It is priced in the range of 7.90%-7.96%, 25-35 basis points higher than similar maturity government securities, making the borrowing cost less than any term bank loan.
Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1874.00 |
| Dr. Reddys Lab | 1295.00 |
| Cipla | 1321.95 |
| Zydus Lifesciences | 946.80 |
| Lupin | 2271.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: